Document:

Exhibit 10.1

 

INDEMNIFICATION
AGREEMENT

 

This Indemnification Agreement (“Agreement”)
is effective as of July 15, 2005 by and between MedQuist Inc. (the “Company”),
and John Simmons (“Indemnitee”).

 

WHEREAS, the Company desires to attract and
retain the services of highly qualified individuals, such as Indemnitee, to
serve the Company and its subsidiaries as directors, officers and in other
capacities;

 

WHEREAS, the Company and Indemnitee recognize
the continued difficulty in obtaining liability insurance for the directors,
officers, employees and other agents of the Company, the significant increases
in the cost of such insurance and the general reductions and limitations in the
coverage of such insurance;

 

WHEREAS, the Company and the Indemnitee
further recognize the substantial increase in corporate litigation in general,
subjecting directors, officers, employees and other agents serving corporations
to expensive litigation risks at the same time as the availability and coverage
of liability insurance has been severely limited;

 

WHEREAS, the Company has adopted bylaws (the “Bylaws”)
providing for the indemnification of directors, officers, employees and other
agents of the Company, including persons serving at the request of the Company
in such capacities with other corporations or enterprises, as authorized by New
Jersey law;

 

WHEREAS, the Bylaws and New Jersey law, by
their non-exclusive nature, permit agreements between the Company and its
directors, officers, employees and other agents with respect to indemnification
of such persons; and

 

WHEREAS, in order to induce Indemnitee to
accept a position with the Company as a director, officer or in another
capacity or capacities and/or continue to provide services to the Company as a
director, officer or in another capacity or capacities, the Company wishes to
provide for the indemnification of, and the advancement of expenses to,
Indemnitee to the maximum extent now or hereafter permitted by law;

 

NOW, THEREFORE, the Company and Indemnitee
hereby agree as follows.

 

1.                                       Indemnification.

 

(a)                                  Third Party
Proceedings.  The Company shall
indemnify Indemnitee if Indemnitee is or was a party or is threatened to be
made a party to any threatened, pending or completed action, suit, proceeding
or any arbitration or other alternative dispute resolution mechanism, whether
civil, criminal, administrative or investigative (other than an action by or in
the right of the Company) by reason of the fact that Indemnitee is or was a
director, officer, employee or agent of the Company, or any subsidiary of the
Company, or by reason of the fact that Indemnitee is or was serving at the
request of the Company as a director, officer, employee 

 

 

or agent of another corporation, partnership,
joint venture, trust or other enterprise, against expenses (including attorneys’
fees), judgments, fines and amounts paid in settlement (if such settlement is
approved in advance by the Company, which approval shall not be unreasonably
withheld) actually and reasonably incurred by Indemnitee in connection with
such action, suit or proceeding if Indemnitee acted in good faith and in a
manner Indemnitee reasonably believed to be in or not opposed to the best
interests of the Company, and, with respect to any criminal action or
proceeding, had no reasonable cause to believe Indemnitee’s conduct was
unlawful.  The termination of any action,
suit or proceeding by judgment, order, settlement, conviction, or upon a plea
of nolo contendere or its equivalent, shall not, of itself, create a
presumption that Indemnitee did not act in good faith and in a manner which
Indemnitee reasonably believed to be in or not opposed to the best interests of
the Company, and, with respect to any criminal action or proceeding, had
reasonable cause to believe that Indemnitee’s conduct was unlawful.

 

(b)                                 Proceedings By or
in the Right of the Company.  The
Company shall indemnify Indemnitee if Indemnitee was or is a party or is
threatened to be made a party to any threatened, pending or completed action or
suit by or in the right of the Company or any subsidiary of the Company to
procure a judgment in its favor by reason of the fact that Indemnitee is or was
a director, officer, employee or agent of the Company, or any subsidiary of the
Company, or by reason of the fact that Indemnitee is or was serving at the
request of the Company as a director, officer, employee or agent of another
corporation, partnership, joint venture, trust or other enterprise, against
expenses (including attorneys’ fees) and, to the fullest extent permitted by law,
amounts paid in settlement, actually and reasonably incurred by Indemnitee in
connection with the defense or settlement of such action or suit if Indemnitee
acted in good faith and in a manner Indemnitee reasonably believed to be in or
not opposed to the best interests of the Company, except that no
indemnification shall be made in respect of any claim, issue or matter as to
which Indemnitee shall have been adjudged to be liable to the Company unless
and only to the extent that the New Jersey court or the court in which such
action or suit was brought shall determine upon application that, despite the
adjudication of liability but in view of all the circumstances of the case,
Indemnitee is fairly and reasonably entitled to indemnity for such expenses which
the New Jersey court or such other court shall deem proper.

 

(c)                                  Mandatory Payment
of Expenses.  To the extent that
Indemnitee has been successful on the merits or otherwise in defense of any
action, suit or proceeding referred to in Sections 1(a) or (b) hereof,
or in defense of any claim, issue or matter therein, Indemnitee shall be
indemnified against expenses (including attorneys’ fees) actually and
reasonably incurred by Indemnitee in connection therewith.

 

2.                                       Advancement
of Expenses; Notice; Indemnification Procedure.

 

(a)                                  Advancement of
Expenses.  The Company shall advance
all expenses incurred by Indemnitee in connection with the investigation,
defense, settlement or appeal of any civil or criminal action, suit or
proceeding referenced in Section 1(a) or (b) hereof (but not
amounts actually paid in settlement of any such action, suit or
proceeding).  Indemnitee hereby
undertakes to repay such amounts advanced only if, and to the extent that, it
shall ultimately be determined that Indemnitee is not entitled to be
indemnified by the Company as authorized hereby.

 

2

 

(b)                                 Notice of
Indemnification Claim; Cooperation by Indemnitee.  Indemnitee shall, as a condition precedent to
his or her right to be indemnified under this Agreement, give the Company
notice in writing as soon as practicable of any claim made against Indemnitee
for which indemnification will or could be sought under this Agreement. Notice
to the Company shall be directed to the General Counsel of the Company at the
address indicated on the signature page of this Agreement (or such other
address as the Company shall designate in writing to Indemnitee). Notice shall
be deemed received as provided in Section 13 hereof.  Indemnitee also shall provide the Company
such information and cooperation as the Company may reasonably require and as
shall be within Indemnitee’s power.

 

(c)                                  Indemnification
Procedure.  Any indemnification
and/or advances provided for in Sections 1 and 2 hereof shall be made no later
than thirty (30) days after receipt of the written request of Indemnitee.  If a claim under this Agreement, under any
statute, or under any provision of the Company’s Certificate of Incorporation
or Bylaws providing for indemnification, is not paid in full by the Company
within thirty (30) days after a written request for payment thereof has first
been received by the Company, Indemnitee may at any time thereafter bring an
action against the Company to recover the unpaid amount of the claim.  It shall be a defense to any such action
brought by Indemnitee (other than an action brought to enforce a claim for
expenses incurred in connection with any action, suit or proceeding in advance
of its final disposition) that Indemnitee has not met the standards of conduct
which make it permissible under applicable law for the Company to indemnify
Indemnitee for the amount claimed. 
Notwithstanding the foregoing, Indemnitee shall be entitled to receive
advancements of expenses pursuant to Section 2(a) hereof unless and
until such defense may be finally adjudicated by court order or judgment from
which no further right of appeal exists. 
It is the intention of the parties that if the Company contests
Indemnitee’s right to indemnification, the question of Indemnitee’s right to
indemnification shall be for the court to decide, and neither the failure of
the Company (including its Board of Directors, any committee or other subgroup
of the Board of Directors, independent legal counsel, or its stockholders) to
have made a determination that indemnification of Indemnitee is proper in the
circumstances because Indemnitee has met the applicable standard of conduct
required by applicable law, nor an actual determination by the Company
(including it Board of Directors, any committee or other subgroup of the Board
of Directors, independent legal counsel, or its stockholders) that Indemnitee
has not met such applicable standard of conduct, shall create a presumption
that Indemnitee has or has not met the applicable standard of conduct.

 

(d)                                 Notice to Insurers.  If, at the time of the receipt of a notice of
a claim pursuant to Section 2(b) hereof, the Company has director and
officer liability insurance in effect, the Company shall give prompt notice of
the commencement of such proceeding to the insurer in accordance with the
procedures set forth in the applicable policy. 
The Company shall thereafter take all action it deems reasonably
necessary or advisable to cause such insurers to pay, on behalf of the
Indemnitee, all amounts payable as a result of such proceeding in accordance
with the terms of such policies.

 

(e)                                  Selection of
Counsel.  In the event the Company
shall be obligated under Section 2(a) hereof to pay the expenses of
any proceeding against Indemnitee, the Company shall be

 

3

 

entitled to assume the defense of such
proceeding, with counsel approved by Indemnitee (such approval not to be
unreasonably withheld), upon the delivery to Indemnitee of written notice of
its election to do so.  After delivery of
such notice, approval of such counsel by Indemnitee and the retention of such
counsel by the Company, the Company will not be liable to Indemnitee under this
Agreement for any fees of counsel subsequently incurred by Indemnitee with
respect to the same proceeding, provided that Indemnitee shall have the right
to employ his or her own counsel in any such proceeding at Indemnitee’s own
expense, and provided further that Indemnitee shall have the right to employ
his or her own counsel in any such proceeding at the Company’s expense if (i) employment
of counsel by Indemnitee has been previously authorized by the Company, (ii) Indemnitee
shall have reasonably concluded that there may be a conflict of interest
between the Company and Indemnitee in the conduct of any such defense, or (iii) the
Company shall not, in fact, have employed counsel to assume the defense of such
proceeding.

 

3.                                       Additional Indemnification Rights;
Nonexclusivity.

 

(a)                                  Scope of Indemnification Rights. 
Notwithstanding any other provision of this Agreement, the Company
hereby agrees to indemnify the Indemnitee to the fullest extent permitted by
law, notwithstanding that such indemnification is not specifically authorized
by the other provisions of this Agreement, the Company’s Certificate of
Incorporation, Bylaws or by statute.  In
the event of any change, after the date of this Agreement, in any applicable
law, statute, or rule which expands the right of a New Jersey corporation
to indemnify a member of its board of directors or an officer or other agent,
such changes shall be incorporated automatically into Indemnitee’s rights and
the Company’s obligations under this Agreement without further action of the
parties.  In the event of any change in
any applicable law, statute or rule which narrows the right of a New
Jersey corporation to indemnify a member of its board of directors or an
officer or other agent, such changes, to the extent not otherwise required by
such law, statute or rule to be applied to this Agreement shall have no
effect on this Agreement or the rights and obligations of the parties
hereunder.

 

(b)                                 Nonexclusivity.  The
indemnification provided by this Agreement shall not be deemed exclusive of any
rights to which Indemnitee may be entitled under the Company’s Certificate of
Incorporation, Bylaws, any other agreement, any vote or approval of Company
stockholders or disinterested Directors, New Jersey law, or otherwise, both as
to action in Indemnitee’s official capacity and as to action in another capacity
while holding such office.

 

(c)                                  Continuing Right.  All agreements and obligations of the Company
included herein shall continue during the period Indemnitee is a director,
officer, employee or other agent of the Company and shall continue thereafter
as long as Indemnitee is subject to any possible claim, action, suit,
proceeding or any arbitration or other alternative dispute resolution
mechanism, whether civil, criminal, administrative or investigative, by reason
of the fact that Indemnity was serving in the capacity referred to herein.

 

4.                                       Partial
Indemnification.  If Indemnitee is
entitled under any provision of this Agreement to indemnification by the
Company for some or a portion of the expenses, judgments, fines or penalties
actually or reasonably incurred by him or her in the investigation, defense,
appeal or settlement of any civil or criminal action, suit or proceeding, but
not, however, for the total 

 

4

 

amount thereof, the Company shall nevertheless
indemnify Indemnitee for the portion of such expenses, judgments, fines or
penalties to which Indemnitee is entitled.

 

5.                                       Mutual
Acknowledgement.  Each of the Company
and Indemnitee acknowledges that in certain instances, Federal law or
applicable public policy may prohibit the Company from providing
indemnification under this Agreement or otherwise.  In particular, the Company and Indemnitee
acknowledge that the Securities and Exchange Commission believes that
indemnification for liabilities arising under the Federal securities laws is
against public policy and, therefore, is unenforceable.  Indemnitee understands and acknowledges that
the Company has undertaken or may be required in the future to undertake with
the Securities and Exchange Commission to submit the question of
indemnification to a court in certain circumstances for a determination
regarding the Company’s right, in view of such public policy considerations, to
indemnify Indemnitee.

 

6.                                       Officer And
Director Liability Insurance.  The Company
may, from time to time, make a determination whether or not it is practicable
for the Company to obtain and maintain a policy or policies of insurance with
insurance companies providing the directors and officers of the Company with
coverage for losses in connection with acts or omissions by such directors and
officers, or to ensure the Company’s performance of its indemnification
obligations under this Agreement.  Among
other considerations, the Company may weigh the costs of obtaining such
insurance coverage against the protection afforded by such coverage.  In all policies of director and officer
liability insurance, Indemnitee will be named as an insured in such a manner as
to provide Indemnitee the same rights and benefits as are accorded to the most
favorably insured of the Company’s directors, if Indemnitee is a director; or
of the Company’s officers, if Indemnitee is not a director of the Company but
is an officer.  Notwithstanding the
foregoing, the Company shall have no obligation to obtain or maintain such
insurance.

 

7.                                       Severability.  Nothing in this Agreement is
intended to require or shall be construed as requiring the Company to do or
fail to do any act in violation of applicable law. The Company’s inability,
pursuant to court order, to perform its obligations under this Agreement shall
not constitute a breach of this Agreement. 
If this Agreement or any portion hereof shall be invalidated on any
ground by any court of competent jurisdiction, then the Company shall
nevertheless indemnify Indemnitee to the full extent permitted by any
applicable portion of this Agreement that shall not have been invalidated, and
the balance of this Agreement not so invalidated shall be enforceable in
accordance with its terms.

 

8.                                       Exceptions.  Notwithstanding any other provision herein to
the contrary, the Company shall not be obligated pursuant to the terms of this
Agreement:

 

(a)                                  Claims Initiated
by Indemnitee.  To indemnify or
advance expenses to Indemnitee with respect to proceedings or claims initiated
or brought voluntarily by Indemnitee and not by way of defense, except with
respect to proceedings brought to establish or enforce a right to
indemnification under this Agreement or any other statute or law or otherwise
as required under 14A:3-5 of the New Jersey Business Corporation Act, but such
indemnification or advancement of expenses may be provided by the Company in
specific cases if the Board of Directors has approved the initiation or
bringing of such suit; or

 

5

 

(b)                                 Lack of Good Faith.  To indemnify Indemnitee for any expenses
incurred by the Indemnitee with respect to any proceeding instituted by
Indemnitee to enforce or interpret this Agreement, if a court of competent
jurisdiction determines that each of the material assertions made by the
Indemnitee in such proceeding was not made in good faith or was frivolous; or

 

(c)                                  Duplication of
Payments.  To indemnify Indemnitee
for expenses or liabilities of any type whatsoever (including, but not limited
to, judgments, fines, ERISA excise taxes or penalties, and amounts paid in
settlement) which actually have been paid to Indemnitee under a valid and
collectible insurance policy, a provision of the Company’s Certificate of
Incorporation or Bylaws, or another valid and enforceable indemnity agreement;
or

 

(d)                                 Claims Under Section 16(b) of
1934 Act.  To indemnify Indemnitee
for expenses and an accounting of profits arising from the purchase and sale by
Indemnitee of securities in violation of Section 16(b) of the
Securities Exchange Act of 1934, as amended, or any successor statute.

 

9.                                       Exceptions
Under New Jersey Law. 
Notwithstanding any other provision of this Agreement, pursuant to the
New Jersey Business Corporation Act, no indemnification shall be made under
this Agreement to or on behalf of the Indemnitee if a judgment or other final
adjudication adverse to the Indemnitee establishes that the Indemnitee’s acts
or omissions (a) were in breach of Indemnitee’s duty of loyalty to the
Company or its shareholders (as defined in 14A:2-7(3) of the New Jersey
Business Corporation Act), (b) were not in good faith or involved a
knowing violation of law, or (c) resulted in receipt by the Indemnitee of
an improper personal benefit.

 

10.                                 Construction Of
Certain Phrases.  For purposes of
this Agreement, the following terms and references shall have the following
meanings:

 

(a)                                  References to the “Company”
shall include, in addition to the resulting corporation in any consolidation,
merger or similar business combination, any constituent corporation (including
any constituent of a constituent) absorbed in a consolidation or merger or
similar business combination which, if its separate existence had continued,
would have had power and authority to indemnify its directors, officers, and
employees or agents, so that if Indemnitee is or was a director, officer,
employee or agent of such constituent corporation, or is or was serving at the
request of such constituent corporation as a director, officer, employee or
agent of another corporation, partnership, joint venture, trust or other
enterprise, Indemnitee shall stand in the same position under the provisions of
this Agreement with respect to the resulting or surviving corporation as
Indemnitee would have with respect to such constituent corporation if its
separate existence had continued.

 

(b)                                 References to “other
enterprises” shall include employee benefit plans;

 

(c)                                  References to “fines”
shall include any excise taxes assessed on Indemnitee with respect to an
employee benefit plan;

 

6

 

(d)                                 References to “serving
at the request of the Company” shall include any service as a director,
officer, employee or agent of the Company which imposes duties on, or involves
services by, such director, officer, employee or agent with respect to an
employee benefit plan, its participants, or beneficiaries; and

 

(e)                                  If Indemnitee acted
in good faith and in a manner Indemnitee reasonably believed to be in the
interest of the participants and beneficiaries of an employee benefit plan,
Indemnitee shall be deemed to have acted in a manner “not opposed to the best
interests of the Company” as referred to in this Agreement.

 

11.                                 Counterparts.  This Agreement may be executed in one or more
counterparts, each of which shall constitute an original.

 

12.                                 Successors And
Assigns.  This Agreement shall be
binding upon the Company and its successors and assigns, and shall inure to the
benefit of Indemnitee and Indemnitee’s estate, heirs, legal representatives and
assigns.  The Company shall require and
cause any successor (whether direct or indirect, and whether by purchase,
merger, consolidation or otherwise) to agree in writing to assume and agree to
perform this Agreement in the same manner and to the same extent that the
Company would be required to perform if no such succession had taken place.

 

13.                                 Attorneys’ Fees.  In the event that any action is instituted by
Indemnitee under this Agreement to enforce or interpret any of the terms
hereof, Indemnitee shall be entitled to be paid all costs and expenses,
including reasonable attorneys’ fees, incurred by Indemnitee with respect to
such action, unless as a part of such action, the court of competent
jurisdiction determines that each of the material assertions made by Indemnitee
as a basis for such action were not made in good faith or were frivolous.  In the event of an action instituted by or in
the name of the Company under this Agreement or to enforce or interpret any of
the terms of this Agreement, Indemnitee shall be entitled to be paid all costs
and expenses, including reasonable attorneys’ fees, incurred by Indemnitee in
defense of such action (including with respect to Indemnitee’s counterclaims
and cross-claims made in such action), unless as a part of such action the
court determines that each of Indemnitee’s material defenses to such action
were made in bad faith or were frivolous.

 

14.                                 Notice.  All notices, requests, demands and other
communications under this Agreement shall be in writing and shall be deemed
duly given (i) if delivered by hand and receipted for by the party
addressee, on the date of such receipt or (ii) if mailed by domestic
certified or registered mail with postage prepaid, on the third business day
after the date postmarked. Addresses for notice to either party are as shown on
the signature page of this Agreement, or as subsequently modified by
written notice.

 

15.                                 Consent To
Jurisdiction.  The Company and
Indemnitee each hereby irrevocably consent to the jurisdiction of the courts of
the State of New Jersey for all purposes in connection with any action or
proceeding which arises out of or relates to this Agreement and agree that any
action instituted under this Agreement shall be brought only in the state
courts of the State of New Jersey.

 

7

 

16.                                 Choice Of Law.  This Agreement shall be governed by and its
provisions construed in accordance with the laws of the State of New Jersey, as
applied to contracts between New Jersey residents entered into and to be
performed entirely within New Jersey without regard to the conflict of law
principles thereof.

 

17.                                 Period Of
Limitations. No legal action shall be brought and no cause of action shall
be asserted by or in the right of the Company against Indemnitee, Indemnitee’s
estate, spouse, heirs, executors or personal or legal representatives after the
expiration of two years from the date of accrual of such cause of action, and
any claim or cause of action of the Company shall be extinguished and deemed
released unless asserted by the timely filing of a legal action within such
two-year period; provided, however, that if any shorter period of limitations
is otherwise applicable to any such cause of action, such shorter period shall
govern.

 

18.                                 Subrogation.  In the event of payment under this Agreement,
the Company shall be subrogated to the extent of such payment to all of the
rights of recovery of Indemnitee, who shall execute all documents required and
shall do all acts that may be necessary to secure such rights and to enable the
Company effectively to bring suit to enforce such rights.

 

19.                                 Amendment;
Termination. No amendment, modification, termination or cancellation of
this Agreement shall be effective unless it is in writing signed by both the parties
hereto. No waiver of any of the provisions of this Agreement shall be deemed or
shall constitute a waiver of any other provisions hereof (whether or not
similar), nor shall any such waiver constitute a continuing waiver.

 

20.                                 No Construction as
Employment Agreement.  Nothing
contained in this Agreement shall be construed as giving Indemnitee any right
to continue in the employment of the Company.

 

21.                                 Entire Agreement.
This Agreement sets forth the entire understanding between the parties hereto
and supersedes and merges all previous written and oral negotiations,
commitments, understandings and agreements relating to the subject matter
hereof between the parties hereto.

 

[signatures on
following page]

 

8

 

[signature page –
Indemnification Agreement]

 

 

IN WITNESS WHEREOF, the parties hereto have
executed this Agreement as of the date first above written.

 

	
  COMPANY:

  	
   

  
	
   

  	
   

  
	
  MEDQUIST INC.

  	
   

  
	
   

  	
   

  
	
  By:

  	
   

  	
   

  
	
   

  	
  Howard S. Hoffmann, CEO

  	
   

  
	
   

  	
   

  
	
  Address for service:

  	
   

  
	
   

  	
   

  
	
  MedQuist Inc.

  	
   

  
	
  Attn: General Counsel

  	
   

  
	
  1000 Bishops Gate Blvd., Suite 300

  	
   

  
	
  Mt. Laurel, NJ 08054

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  AGREED TO AND ACCEPTED:

  	
   

  
	
   

  	
   

  
	
  INDEMNITEE:

  	
   

  
	
   

  	
   

  
	
  JOHN SIMMONS

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  Signature

  	
   

  
	
   

  	
   

  
	
  Address for service:

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
				

 

9Exhibit 10.1

 

PATENT LICENCE AGREEMENT

(ADAIR PATENT RIGHTS)

(MEDI-493)

 

between

 

CELLTECH THERAPEUTICS
LIMITED

 

and

 

MEDIMMUNE INC.

 

 

THIS AGREEMENT is made the 19 day of January 1998

BETWEEN

 

1.                                       CELLTECH THERAPEUTICS LIMITED (registered in
England No. 1472269) whose principal place of business is at 216 Bath Road,
Slough, Berkshire SL1 4EN, England (“Celltech”); and

 

2.                                       MEDIMMUNE INC. of 35 West Watkins Mill Road, Gaithersburg, MD  20878, USA (“Licensee”).

 

WHEREAS

 

A.                                   Celltech claims John Robert Adair, Diljeet
Singh Athwal and John Spencer Emtage whilst employees of Celltech in or about December 1989
developed certain processes and products in the field of genetic engineering of
monoclonal antibodies which are the subject of the Adair Patent Rights, and

 

B.                                     Celltech has filed and prosecuted patent
applications and/or been granted patents in the Patent Offices of the United
Kingdom and elsewhere in respect of such processes and products, and

 

C.                                     Celltech wishes to grant and the Licensee
wishes to accept a licence under the Adair Patent Rights on the terms set out
below.

 

NOW IT IS HEREBY AGREED as follows:

 

1.                                      DEFINITIONS

 

In this Agreement the
following words and phrases shall have the following meanings unless the
context otherwise requires:

 

	
  1.1

  	
   

  	
  “Adair Patent Rights”

  	
   

  	
  shall mean the Patent Rights short particulars of
  which are set out in Schedule 1 hereto and sometimes referred to
  collectively or individually as “the Adair Patent”.

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  1.2

  	
   

  	
  “Affiliate”

  	
   

  	
  shall mean any company, partnership or other entity
  which directly or indirectly Controls, is Controlled by or is under common
  Control with the relevant party to this Agreement.

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  1.3

  	
   

  	
  “Control”

  	
   

  	
  shall mean ownership of more than 50% of
  the issued share capital or the legal power to direct or cause the direction
  of the general management and policies of the party in question.

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  1.4

  	
   

  	
  “Commencement Date”

  	
   

  	
  shall mean the date hereof;

  

 

 

	
  1.5

  	
   

  	
  “Field”

  	
   

  	
  shall mean the field of human therapy and
  prophylaxis.

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  1.6

  	
   

  	
  “Net Receipts”

  	
   

  	
  shall mean all monies received by or on behalf of
  the Licensee or by or on behalf of its sub-licensees in respect of the sale
  of Product(s), less the following items to the extent that they are paid or
  allowed and included in the invoice price:

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
  i)                                         normal discounts actually granted;

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
  ii)                                      credits allowed for Products returned or
  not accepted by customers: disallowed reimbursements;

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
  iii)                                   packaging, transportation and pre-paid
  insurance charges on shipments or deliveries to customers;

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
  iv)                                  sales, customs, and excise taxes actually
  incurred and paid by the Licensee or its sub-licensees in connection with the
  sale or delivery of Product to customers.

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
  Upon any sale or other disposal of Product by or
  on behalf of Licensee or its sub-licensee other than a bona fide arms length
  transaction exclusively for money or upon any disposal of the Product for
  purposes which do not result in a disposal of such Product in consideration
  of sales revenue customary in the country of use, such sale, other disposal
  or use shall be deemed to constitute a sale at the then current maximum
  selling price in the country in which such sale, other disposal or use
  occurs.

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
  For the avoidance of doubt, the supply of Product
  free of charge for use in clinical studies or to third parties for research
  evaluation purposes shall not be included in this provision.

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  1.7

  	
   

  	
  “Patent Rights”

  	
   

  	
  shall mean patent applications or patents,
  inventor certificates, utility certificates, improvement patents and models
  and certificates of addition and includes any divisions, renewals,
  continuations, extensions or re-issues thereof anywhere in the Territory and
  supplementary protection certificates.

  

 

3

 

	
  1.8

  	
   

  	
  “Product”

  	
   

  	
  shall mean antibodies or fragments thereof or any
  formulation containing the same of which the Licensee is the proprietor or is
  otherwise licensed to develop, make, have made, use or sell, and which bind
  to the respiratory syncitical virus (MEDI-493).

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  1.9

  	
   

  	
  “Territory”

  	
   

  	
  shall mean worldwide.

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  1.10

  	
   

  	
  “Valid Claim”

  	
   

  	
  shall mean a claim of an issued, unexpired patent
  included within the Adair Patent Rights which has not been held invalid or
  unenforceable in an unappealed or unappealable decision of a court or
  competent body having jurisdiction thereof.

  

 

2.                                      GRANT OF RIGHTS

 

2.1                                 Celltech hereby grants to the Licensee with
effect from the Commencement Date a non-exclusive licence under the Adair
Patent Rights to develop, make, have made, use and sell Products in the Field
and Territory;

 

2.2                                 Licensee shall be entitled to sublicense the
rights granted in clause 2.1 on terms which are subject and subordinate to the
terms of this Agreement and at least 14 days prior to the execution of any
sublicence, Licensee shall give written notice to Celltech of the identity of
the sublicensee together with details of the antibody covered by the sublicence
and Licensee shall provide Celltech with a redacted copy (excluding financial
and other relevant terms) of any sub-licence granted pursuant to this Clause
2.2 promptly after its execution.

 

3.                                      PAYMENT

 

3.1                                 In consideration of the Licences granted in
clause 2 the Licensee shall pay to Celltech an initial sum of [***] against
Celltech’s invoice to be issued on the Commencement Date.

 

3.2                                 In further consideration of the licenses
granted in Clause 2 the Licensee shall pay to Celltech annually upon each
anniversary of the Commencement Date [****] which amount may be offset in each
year up to a maximum of [***] against up to half the amount of any royalties
payable under Clause 3.3 by the Licensee in the same year.

 

3.3                                 In further consideration of the licences
granted in Clause 2 the Licensee shall pay to Celltech a royalty at the rate of
[***] of Net Receipts from all Products sold where the manufacture or sale of
the Product in a country of the Territory would, but for the licence granted
hereby, infringe a Valid Claim.

 

3.4                                 Payments due under Clause 3.3 shall be made
within 30 days of the end of each calendar quarter in respect of royalties
accruing on Net Receipts during that

 

4

 

calendar quarter.  Payments due under Clause 3.2 shall be made
within 30 days of each anniversary of the Commencement Date.

 

3.5                                 All payments due under this Agreement:

 

3.5.1        are exclusive of any Value Added Tax or
similar tax which shall be payable in addition by the Licensee.

 

3.5.2        shall
be made in pounds sterling or to the credit of a bank account to be designated
in writing by Celltech.  Payments due to
Celltech in a currency other than pounds sterling shall first be calculated in
the relevant foreign currency and then converted to pounds sterling at the rate
of exchange of the currency in the country in which such payments fall due, as
determined by the Financial Times Spot Rate for the pound in London first
published on the day after the last business day of the calendar quarter in
respect of which the royalties are payable.

 

3.5.3        shall be made in full without set-off and
free and clear of and without any deduction or withholding for or on account of
taxes, duties, levies, imposts, fees or charges and other duties that may be
imposed by or under the authority of any government or public authority as far
as is legally possible save with regard to withholding tax.  Where any sum due to be paid to Celltech
hereunder is subject to any withholding or similar tax the parties shall take
all reasonable steps to do all such acts and things and to sign all such deeds
and documents as will enable them to take advantage of any applicable double
taxation agreements with the object of paying the sums due to Celltech and on a
gross basis.  In the event there is no
applicable double taxation agreement the Licensee shall pay such withholding or
similar tax, deduct the relevant amount from the payment due to Celltech, and
secure and send to Celltech proof of such withholding or similar tax in a form
satisfactory to Celltech as evidence of such payment.

 

3.6                                 Where Celltech does not receive payment of
any sums due to it within the period specified hereunder in respect thereof
interest shall accrue on the sum outstanding at the rate of 2% above the “Base
Rate” from time to time of Midland Bank Plc calculated on a daily basis without
prejudice to Celltech’s right to receive payment on the due date therefor.

 

3.7                                 If restrictions on the transfer of currency
exist in any country of the Territory such as to prevent the Licensee from
making payments in the United Kingdom, the Licensee shall take all reasonable
steps to obtain a waiver of such restrictions or otherwise enable the Licensee
to make such payments failing which the Licensee may make the royalty payments
due upon sales in such country in local currency and deposit such payments in a
local bank or other depository designated by Celltech.

 

5

 

4.                                      RECORDS AND STATEMENTS

 

4.1                                 The Licensee agrees to keep true and accurate
records and books of account containing all data necessary for the calculation
of the royalties payable to Celltech under clause 3.3.  At Celltech’s request and expense the
Licensee shall permit a representative of a firm of independent accountants,
appointed by Celltech and acceptable to the Licensee (such acceptance not to be
unreasonably withheld or delayed), upon reasonable notice and at reasonable
times, to inspect such books and records for the purposes of verifying the
royalties payable to Celltech by the Licensee. 
If the royalties are found to be in error such that royalties were
underpaid, then the Licensee shall promptly make good any deficiency including
making payments of interest on outstanding sums in accordance with the current
rate subsisting pursuant to clause 3.6 and if any deficiency of 5% or more is
found to have arisen the costs of the said inspection shall be borne by the
Licensee.

 

4.2                                 The Licensee shall prepare a statement in
respect of each calendar quarter of this Agreement which shall show for the
calendar quarter in question the Net Receipts of sales by it or any
sub-licensee of Products on a country by country basis, details of the
quantities of Products manufactured and/or sold in each country in respect of
which there are Adair Patent Rights licensed under this Agreement and the
royalty and VAT due to Celltech thereon pursuant to clause 3 above.  Such statement shall be submitted to Celltech
within 30 days of the end of each calendar quarter to which it relates together
with a remittance for the royalties due to Celltech.  Celltech shall simultaneously raise and send
a VAT invoice to the Licensee.  If
Celltech shall give notice to the Licensee within ninety (90) days of the
receipt of any such statement that it does not accept such statement, the
statement shall be certified by a firm of independent accountants appointed and
paid for by Celltech and acceptable to Licensee (such acceptance not to be
unreasonably withheld or delayed).  The
Licensee shall make available all books and records necessary for the purpose
of such clarification.  Following any
such clarification the parties shall make any adjustments necessary in respect
of royalties already paid to Celltech in relation to the period in question.

 

5.                                      PATENT PROSECUTION AND
MAINTENANCE

 

5.1                                 Celltech hereby undertakes that at its own
expense it will:

 

5.1.1        prosecute such of the Adair Patent Rights
which are patent applications diligently to grant so as to secure the broadest
protection obtainable so far as it is reasonable to do so with particular
reference to Celltech’s commercial considerations; and

 

5.1.2        pay all renewal fees for the Adair Patent
Rights for the full term thereof so far as it is reasonable to do so with
particular reference to Celltech’s commercial considerations.

 

6

 

6.                                      THIRD PARTY PATENTS AND
INFRINGEMENTS

 

6.1                                 The Licensee shall promptly notify Celltech
in writing of any infringement or threatened infringement or improper or
unlawful use of or of any challenge to the validity of the Adair Patent Rights
of which it is or becomes aware and shall provide Celltech with evidence
thereof.

 

6.2                                 With respect to Adair Patent Rights as
licensed herein Celltech undertakes and agrees to take all such steps and
proceedings and to do all such other acts and things as may in Celltech’s sole
discretion be necessary to restrain any infringement or improper or unlawful
use of or to defend any challenge to the validity of the Adair Patent Rights in
the Territory and the Licensee shall permit Celltech to have the sole conduct
of any such steps and proceedings including the right to settle them whether or
not the Licensee is a party to them. 
Licensee hereby agrees to cooperate fully with Celltech at Licensee’s
own cost and expense to the extent such cost and expense is reasonable lending
its name to the proceedings as may be necessary.  Celltech shall be entitled to retain any and
all monies received from such proceedings subject to the Licensee being
entitled to recover those expenses incurred by the Licensee.

 

7.                                      LIABILITY

 

7.1                                 Celltech gives no representation or warranty
that the Adair Patent Rights which are patent applications will be granted or
if granted will be valid nor that the exercise of the rights granted to the
Licensee hereunder will not infringe the Patent Rights or other intellectual
property rights vested in Celltech or in any third party.

 

7.2                                 The Licensee hereby undertakes and agrees to
be solely responsible at its own cost and expense for dealing with and for any
liability, loss, damage, cost or expense arising from any contractual tortious
or other claims or proceedings by third parties concerning the development,
manufacture, marketing or sale of Products and in particular product liability
claims or proceedings and shall promptly indemnify Celltech against all such
liability, loss, damage, cost or expense.

 

7.3                                 No rights are granted save for those
expressly granted herein and no rights shall arise by implication, estoppel or
otherwise, and the Licensee acknowledges that it must satisfy itself as to the
need for licenses under intellectual property rights vested in Celltech (other
than Adair Patent Rights) and in any third parties in order to exploit the
rights granted herein.

 

7.4                                 The obligations of the Licensee under this
clause 7 shall survive the termination of this Agreement for whatever reason.

 

8.                                      SECURITY/CONFIDENTIALITY

 

8.1                                 Both parties undertake and agree not at any
time for any reason whatsoever to disclose or permit to be disclosed to any
third party or make use of or permit to be

 

7

 

made use of any trade secrets
or confidential information relating to the business affairs or finances of the
other which comes into their possession pursuant to this Agreement save as may
be expressly permitted hereunder and then only having imposed corresponding
obligations of confidence upon the recipient.

 

8.2                                 The obligations of confidence referred to in
this clause 8 shall not extend to any information which:

 

8.2.1        is or shall become generally available to the
public otherwise than by reason of a breach by the recipient party of the
provisions of this clause 8;

 

8.2.2        is known to the recipient party and is at its
free disposal prior to its receipt from the other;

 

8.2.3        is subsequently disclosed to the recipient
party without obligations of confidence by a third party owing no such
obligations in respect thereof.

 

8.2.4        is required to be disclosed by order of a
court or governmental agency or authority or for regulatory purposes or to meet
the requirements of any Stock Exchange to which the parties may be subject
provided that the party making such disclosure shall without delay notify the
other party in writing of such requirement to make disclosure and shall not
make such disclosure prior to such notification to the other party.

 

8.3           The obligations of each party under this clause
8 shall survive the termination of this Agreement for whatever reason.

 

8.4           Notwithstanding the foregoing, Licensee may
provide confidential information to its sub-licensees, contract manufacturers
of Product, marketing and distribution partners for Product always provided
that such sub-Licensees, contract manufacturers and partners are bound by
obligations of confidentiality and limited use equivalent to those of Licensee
herein.

 

9.                                      TERM

 

9.1                                 Subject to the provisions for earlier
termination contained herein, this Agreement shall commence on the Commencement
Date and shall continue until expiry of the last to expire of the Adair Patent
Rights.

 

10.                               TERMINATION

 

10.1                           Subject to the provisions of clause 11.3:

 

10.1.1      Either Celltech or the Licensee may terminate
this Agreement immediately by notice in writing to the other if the other party
commits a breach of this Agreement which in the case of a breach capable of
remedy shall not have been remedied by such other party within 30 days of the
receipt by the other of a notice identifying the breach and requiring its
remedy; or

 

8

 

10.1.2                  Intentionally omitted.

 

10.2                           Licensee shall have the right to terminate
the Agreement at any time by thirty (30) days prior written notice to Celltech.

 

11.                               CONSEQUENCES OF TERMINATION

 

11.1                           If this Agreement is terminated for any
reason, any and all licences granted hereunder shall terminate with effect from
the date of termination.

 

11.2                           If this Agreement is terminated, any
sub-licensees of the Licencee may request, and if requested and if Celltech
agrees, obtain its own licence under the Adair Patent Rights for Product in the
Field directly with Celltech on the same terms and conditions as herein
contained.

 

11.3                           Termination of this Agreement for whatever
reason or expiration of this Agreement shall not affect the accrued rights of
the parties arising in any way out of this Agreement as at the date of
termination and in particular but without limitation the right to recover damages
against the other and all provisions which are expressed to survive this
Agreement shall remain in full force and effect.

 

12.                               ASSIGNMENT

 

12.1                           Subject to the provisions of clause 12.2
below and save as otherwise provided herein neither party shall assign,
transfer, charge, sub-contract or in any other manner make over to any third
party the benefit and/or burden of this Agreement without the prior written
consent of the other which consent shall not be unreasonably withheld or
delayed.

 

12.2                           Celltech shall be entitled without the prior
written consent of the Licensee to assign, transfer, charge or in any manner
make over the benefit and/or burden of this Agreement to an Affiliate or to any
50/50 joint venture company where it is the beneficial owner of 50% of the
issued share capital thereof or to any company with which it may merge or to
any company to which it may transfer substantially all of its assets and
undertaking.

 

12.3                           This Agreement shall be binding upon the
successors and assigns of the parties hereto and the name of a party appearing
herein shall be deemed to include the names of its successors and assigns
provided always that nothing herein shall permit any assignment by either party
except as expressly provided herein.

 

13.                               GOVERNING LAW AND JURISDICTION

 

13.1                           The validity, construction and performance of
this Agreement shall be governed by English law.

 

13.2                           All disputes, claims or proceedings between
the parties relating to the validity, construction or performance of this
Agreement shall be subject to the jurisdiction

 

9

 

of the laws of England to
the jurisdiction of whose courts the parties hereto submit.  Each of the parties consents to the award or
grant of any relief in any such proceedings before the High Court of Justice in
England.  Either party shall have the
right to take proceedings in any
other jurisdiction for the purposes of enforcing a judgement or order obtained
from a Court of Justice in England.

 

14.                               FORCE MAJEURE

 

14.1         Neither party shall be in breach of this
Agreement if there is any total or partial failure of performance by it of its
duties and obligations under this Agreement occasioned by any act of God, fire,
earthquake, act of government or state, war, civil commotion, insurrection,
embargo, prevention from or hindrance in obtaining any raw materials, energy or
other supplies, labour disputes of whatever nature and any other reason beyond
the control of either party.  If either
party is unable to perform its duties and obligations under this Agreement as a
direct result of the effect of one of such reasons, such party shall give
written notice to the other of such inability stating the reason in
question.  The operation of this Agreement
shall be suspended during the period (and only during the period) in which the
reason continues.  Forthwith upon the
reason ceasing to exist the party relying upon it shall give written advice to
the other of this fact.  If the reason
continues for a period of more than 90 days and substantially affects the
commercial basis of this Agreement, the party not claiming under this clause 14
shall have the right to terminate this Agreement upon giving 60 days written
notice of such termination to the other party.

 

15.                               ILLEGALITY

 

15.1         If any provision or term of this Agreement or
any part thereof shall become or be declared illegal, invalid or unenforceable
for any reason whatsoever, including but without limitation by reason of the
provisions of any legislation or other provisions having the force of law or by
reason of any decision of any Court or other body or authority having
jurisdiction over the parties hereto or this Agreement including the EC
Commission or the European Court of Justice, such terms or provisions shall be
divisible from this Agreement and shall be deemed to be deleted from this
Agreement in the jurisdiction in question provided always that if any such
deletion substantially affects or alters the commercial basis of this Agreement
either party shall have the right to terminate this Agreement upon giving 60
days written notice of such termination to the other party.

 

16.                               ENTIRE
AGREEMENT/AMENDMENT/WAIVER/PRESS RELEASES/COSTS

 

16.1         This Agreement embodies and sets forth the
entire agreement and understanding of the parties and supersedes all prior oral
or written agreements, understandings or arrangements relating to the subject
matter of this Agreement.  Neither party
shall be entitled to rely on any agreement, understanding or arrangement which
is not expressly set forth in this Agreement.

 

10

 

16.2                           This Agreement shall not be amended,
modified, varied or supplemented except in writing signed by duly authorised
representatives of the parties.

 

16.3                           No failure or delay on the part of either
party hereto to exercise any right or remedy under this Agreement shall be
construed or operated as a waiver thereof nor shall any single or partial
exercise of any right or remedy under this Agreement preclude the exercise of
any other right or remedy or preclude the further exercise of such right or
remedy as the case may be.  The rights
and remedies provided in this Agreement are cumulative and are not exclusive of
any rights or remedies provided by law.

 

16.4                           The text of any press release or other
communication to be published by or in the media concerning the subject matter
of this Agreement shall require the approval of each party hereto.

 

16.5                           Each of the parties hereto shall be
responsible for its respective legal and other costs incurred in relation to
the preparation of this Agreement.

 

17.                               NOTICE

 

17.1                           Any notice, report or other document required
or permitted to be given under this Agreement shall be in writing and shall be
delivered in person, by courier, by mail or by facsimile and confirmed by mail,
to the address stated below and shall be effective three (3) business days
after despatch by express courier or such mailing:

 

	
  If to Celltech:

  	
   

  	
  Celltech Therapeutics Ltd

  
	
   

  	
   

  	
  216 Bath Road

  
	
   

  	
   

  	
  Slough

  
	
   

  	
   

  	
  Berkshire

  
	
   

  	
   

  	
  SL 1 4EN, England

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  Facsimile: 01753 536632

  
	
   

  	
   

  	
  Attention: Company Secretary

  
	
   

  	
   

  	
   

  
	
  If to Licensee:

  	
   

  	
  MedImmune Inc.

  
	
   

  	
   

  	
  35 West Watkins Mill Road

  
	
   

  	
   

  	
  Gaithersburg MD 20878

  
	
   

  	
   

  	
  USA

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  Facsimile: 001 301 527 4201

  
	
   

  	
   

  	
  Attention: President

  

 

or at such other address as
Celltech or the Licensee may furnish from time to time to the other in writing.

 

11

 

17.2                           All such notices and documents shall be in
the English language.  To prove the
giving of a notice or other document it shall be sufficient to show that it was
despatched.

 

18.                               INTERPRETATION

 

18.1                           The headings in this Agreement are inserted
only for convenience and shall not affect the construction hereof.

 

18.2                           Where appropriate, words denoting a singular
number only shall include the plural and vice versa.

 

18.3                           Reference to any statute or statutory
provision includes a reference to the statute or statutory provision as from
time to time amended, extended or re-enacted.

 

IN WITNESS whereof, duly authorised officers of the
parties hereto have set their hands the year first above written.

 

 

	
  SIGNED by

  	
  )

  	
  /s/

  	
   

  
	
  for and on behalf of

  	
  )

  	
   

  
	
  CELLTECH THERAPEUTICS LIMITED

  	
  )

  	
  /s/

  	
   

  
	
   

  	
  Title

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  SIGNED by

  	
  )

  	
  /s/

  	
   

  
	
  for and on behalf of

  	
  )

  	
   

  
	
  MEDIMMUNE INC.

  	
  )

  	
  /s/

  	
   

  
	
   

  	
  Title

  

 

12

 

SCHEDULE 1

 

ADAIR
PATENT RIGHTS

 

 

 

SCHEDULE 1

 

	
  Celltech Ref. No.:

  	
   

  	
  PA 259

  
	
   

  	
   

  	
   

  
	
  Title:

  	
   

  	
  Humanised
  Antibodies

  
	
   

  	
   

  	
   

  
	
  Subject Matter:

  	
   

  	
  Recombinant human antibodies

  
	
   

  	
   

  	
   

  
	
  Inventors:

  	
   

  	
  Adair, John Robert

  
	
   

  	
   

  	
  Athwal, Diljeet Singh

  
	
   

  	
   

  	
  Emtage, John Spencer

  
	
   

  	
   

  	
   

  
	
  Priority Application Date:

  	
   

  	
  21st December 1989

  
	
  Earliest Publication Date/No:

  	
   

  	
  11th July 1991/WO91/09967

  

 

	
  Territory

  	
   

  	
  Application Date

  	
   

  	
  Application No.

  	
   

  	
  Patent No.

  	
   

  	
  Expiry Date

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Australia

  	
   

  	
  21.12.90

  	
   

  	
  69740/91

  	
   

  	
  646009

  	
   

  	
  21.12.10

  	
   

  
	
  Australia (divisional)

  	
   

  	
  21.12.90

  	
   

  	
  64612/94

  	
   

  	
  664801

  	
   

  	
  21.12.10

  	
   

  
	
  Bulgaria

  	
   

  	
  21.12.90

  	
   

  	
  95018

  	
   

  	
  60462

  	
   

  	
  21.12.10

  	
   

  
	
  Canada

  	
   

  	
  06.03.91

  	
   

  	
  2037607.4

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Canada (divisional)

  	
   

  	
  06.03.91

  	
   

  	
  2129219

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  *Europe

  	
   

  	
  21.12.90

  	
   

  	
  91901433.2

  	
   

  	
  0460167

  	
   

  	
  21.12.10

  	
   

  
	
  *Europe (divisional-1)

  	
   

  	
  21.12.90

  	
   

  	
  94104042.0

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  *Europe (divisional-2)

  	
   

  	
  21.12.90

  	
   

  	
  94202090.0

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Finland

  	
   

  	
  21.12.90

  	
   

  	
  913926

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Hungary

  	
   

  	
  21.12.90

  	
   

  	
  2734/91

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Japan

  	
   

  	
  21.12.90

  	
   

  	
  501864/91

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Norway

  	
   

  	
  21.12.90

  	
   

  	
  913228

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Romania

  	
   

  	
  21.12.90

  	
   

  	
  148282

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  South Korea

  	
   

  	
  21.12.90

  	
   

  	
  700949/91

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  United Kingdom

  	
   

  	
  21.12.90

  	
   

  	
  9117612.3

  	
   

  	
  2246570

  	
   

  	
  21.12.10

  	
   

  
	
  United Kingdom (divisional)

  	
   

  	
  21.12.90

  	
   

  	
  9318912.4

  	
   

  	
  2268745

  	
   

  	
  21.12.10

  	
   

  
	
  USA

  	
   

  	
  21.12.90

  	
   

  	
  08/303569

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  USA

  	
   

  	
  21.12.90

  	
   

  	
  tba

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  USA (divisional)

  	
   

  	
  21.12.90

  	
   

  	
  [***]

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

*Includes: 
Austria, Belgium, Denmark, France, Germany, Greece, Italy,
Liechtenstein, Luxembourg, Netherlands, Spain, Sweden, Switzerland, United
Kingdom

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00087-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00087-of-00352.parquet"}]]